Home > Healthcare > Medical Devices > Therapeutic Devices > Gastrointestinal Bleeding Treatment Market

Gastrointestinal Bleeding Treatment Market Size

  • Report ID: GMI8601
  • Published Date: Mar 2024
  • Report Format: PDF

Gastrointestinal Bleeding Treatment Market Size

Gastrointestinal Bleeding Treatment Market size was valued at USD 808 million in 2023 and is expected to reach USD 1.6 billion by 2032, growing at a CAGR of 7.9% over the analysis period. One of the primary drivers is rising cases of gastrointestinal disorders such as peptic ulcers, gastritis, and colorectal cancer, which lead to bleeding in the digestive tract.

 

Additionally, the rising geriatric population, who are more prone to gastrointestinal bleeding due to age-related changes in the digestive system, is contributing to market growth. For instance, studies have shown that the rate of admission for acute upper GI bleeding increases significantly with age, with a 30-fold increase between the third and ninth decades of life. Moreover, technological advancements in endoscopy procedures and diagnostic imaging techniques have further fuelled market expansion by increasing the diagnosis and treatment adoption of gastrointestinal bleeding.
 

Gastrointestinal bleeding, also known as GI bleeding, refers to any bleeding that occurs in the gastrointestinal tract, which includes the oesophagus, stomach, small intestine, large intestine (colon), rectum, and anus. Gastrointestinal bleeding treatment refers to the medical interventions aimed at stopping or managing bleeding in the gastrointestinal tract. This can include various approaches depending on the cause and severity of the bleeding, such as endoscopic procedures, surgery, and supportive care. The goal is to stabilize the patient, control bleeding, and prevent complications.
 

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Gastrointestinal bleeding treatment market size was USD 808 million in 2023 and is expected to register 7.9% CAGR from 2024-2032 owing to the rising cases of gastrointestinal disorders such as peptic ulcers, gastritis, and colorectal cancer worldwide.

Gastrointestinal bleeding treatment industry from the endoscopic hemostatic devices segment recorded USD 498.8 million in 2023 and is expected to register an appreciable CAGR from 2024-2032 due to their high efficacy and minimally invasive nature.

North America gastrointestinal bleeding treatment industry held 41.6% share in 2023 and is expected to register a commendable CAGR from 2024-2032 due to the high prevalence of gastrointestinal disorders in the region.

CONMED Corporation, Cook Group, ERBE Elektromedizin GmbH, Medtronic PLC, Olympus Corporation, Ovesco Endoscopy AG, Pfizer Inc., STERIS PLC, and US Medical Innovations, are some of the major gastrointestinal bleeding treatment companies worldwide.

Gastrointestinal Bleeding Treatment Market Scope

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 10
  • Tables & Figures: 289
  • Countries covered: 19
  • Pages: 165
 Download Free Sample